peppersite
Metabolic supportsubcutaneous

Cagrilintide / Tirzepatide

CagrilintideTirzepatide

Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.

A blend, not a compound

This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.

Researched for
Metabolic HealthBody CompositionWeight ManagementAppetite Regulation

At a glance

Also called
Cagrilintide + Tirzepatide
Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
Sources differ. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for Cagrilintide / Tirzepatide, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Cagrilintide / Tirzepatide or for anything else, and nothing below has been checked against the study it came from.

Tirzepatide 15.0 mg/week + Cagrilintide 2.4 mg/week (maintenance); sub-maximal example: tirzepatide 10 mg + cagrilintide 1.2 mg
Frequency
Once weekly24-week ramp + open-ended maintenance; or stabilize tirzepatide at 10-15 mg then add cagrilintide for 12+ weeks; or sub-maximal combination as needed
Route
Subcutaneous
Reported by
peptidedosingprotocols.com
What it says[Source: peptidedosingprotocols.com]
Reconstitution, as reported
  • Each vial is reconstituted separately using bacteriostatic water (BAC water). Tirzepatide: 5 mg vial + 1.0 mL BAC = 5 mg/mL; 10 mg vial + 2.0 mL BAC = 5 mg/mL; 10 mg vial + 1.0 mL BAC = 10 mg/mL; 30 mg vial + 3.0 mL BAC = 10 mg/mL. Cagrilintide: 5 mg vial + 2.0 mL BAC = 2.5 mg/mL; 10 mg vial + 2.0 mL BAC = 5.0 mg/mL; 10 mg vial + 1.0 mL BAC = 10.0 mg/mL. Cagrilintide is sensitive, inject BAC water down the vial wall and swirl gently; do not shake (amyloid fibril risk); discard cloudy solution. Label every vial with compound name, concentration, and reconstitution date. Both compounds are stable 28-30 days at 2-8 °C once reconstituted. Standard steps: let vial and BAC water reach room temperature (~10-15 minutes); swab both vial stoppers with alcohol. Do not mix the two compounds in one syringe.
Not yet audited

We have not published an audit on Cagrilintide / Tirzepatide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Tirzepatide lowers appetite, slows digestion and supports insulin sensitivity, while cagrilintide mimics amylin, the fullness hormone the pancreas releases after meals. Researchers link this to three receptor pathways: GLP-1, GIP and amylin, with amylin signaling in the hindbrain, a different brain region from GLP-1. One study in obese rats found greater weight loss from the combination than from either compound alone at sub-maximal doses. No human clinical trial has tested the two together.

In technical termsCombines amylin-receptor agonism (cagrilintide) with GIP/GLP-1 agonism (tirzepatide); studied for appetite regulation and weight management.

Reported side effects

Reported by users: nausea, vomiting and constipation, which can add up because both compounds slow stomach emptying. Gut effects are said to peak often while both doses are being raised, around Weeks 13-16. The source calls raising doses too fast the single biggest cause of dropping out.

Not ruled out: the source notes an amyloid fibril risk if cagrilintide is shaken during mixing, and says cloudy solution is discarded. No human trial has tested this combination, so its side-effect rates are unknown.

Who should avoid it

People using semaglutide: tirzepatide already covers GLP-1 receptors, so semaglutide adds redundancy without a new pathway.

People using retatrutide: it covers GLP-1 and GIP, the same receptors tirzepatide acts on, which adds redundant signaling and side-effect risk.

People using pramlintide: it is a short-acting amylin analog, and cagrilintide already covers amylin signaling.

What gets monitored

At-home blood test (SiPhox Health At-Home Blood Test) is listed as a recommended supply. No specific lab panels or monitoring parameters are named beyond this. (reported by peptidedosingprotocols.com)

Common questions

Can you take cagrilintide and tirzepatide together?

Community protocols describe using both, but not from the same first day. They describe tirzepatide alone for the first 8 weeks (2.5 to 5 mg/week) to confirm gut tolerance, then cagrilintide added at 0.25 mg/week from Week 9, with both given once weekly on the same day at different sites. No human trial has tested the combination.

How much cagrilintide do you take with tirzepatide?

Reported amounts and schedules for Cagrilintide / Tirzepatide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

How far apart should I inject cagrilintide and tirzepatide?

The source says there is no required time gap. Community reports say most users inject both on the same day, a few minutes apart at different sites, while some split them across the week to spread out gut side effects. Both have half-lives of around 5-8 days, so a split of a few days is said not to change overall coverage much.

Can I inject cagrilintide and tirzepatide at the same port (same injection site)?

The source says no. It describes different sites for each compound, such as the abdomen for tirzepatide and the thigh or upper arm for cagrilintide, to reduce local irritation and to show which compound caused a reaction. It also says the two are never mixed in one syringe.

When does cagrilintide appetite suppression kick in?

Cagrilintide has a long half-life of about 7-8 days, so it builds up slowly. Community reports mention noticeable appetite suppression by Week 2-3, with some users reporting changes in the first week. Effects at 0.25 mg/week are described as usually mild, with stronger fullness after stepping up to 0.5-1.0 mg/week.

Is there any combination data for cagrilintide + tirzepatide?

Yes, one preclinical study. Valdecantos et al. (2024) gave both compounds to obese rats and found greater weight loss than with either alone at sub-maximal doses. No human trial has tested the combination as of June 2026.

How does this stack compare to CagriSema?

CagriSema pairs cagrilintide with semaglutide, a GLP-1-only drug, and has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks. An NDA, a new drug application, was filed with the FDA in December 2025. Cagrilintide plus tirzepatide adds GIP activity and covers three pathways instead of two, but it has no human trial data of its own.

How do you reconstitute cagrilintide and tirzepatide?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Cagrilintide / Retatrutide

Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.

CagriSema

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.

Mazdutide

Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.

Retatrutide

Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.

Semaglutide

Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.

Tirzepatide

Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.